<PAGE>
 
   As filed with the Securities and Exchange Commission on January 24, 1997.

                                                     Registration No.  333-_____
 
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549
                             ____________________
                                   FORM S-8
                            REGISTRATION STATEMENT
                                     Under
                              The Securities Act
                              __________________

                             MEDI-JECT CORPORATION
                             ---------------------
            (Exact name of registrant as specified in its charter)

<TABLE>
<CAPTION>
<S> <C>
                          Minnesota                                                                         41-1350192
                          ---------                                                                         ----------
(State or other jurisdiction of incorporation or organization)                                 (I.R.S. Employer Identification No.)
</TABLE>
                              1840 Berkshire Lane
                         Minneapolis, Minnesota 55441
                         ----------------------------
              (Address of principal executive offices) (Zip code)

                            1993 STOCK OPTION PLAN
                                      AND
                            1996 STOCK OPTION PLAN
                             (Full title of plans)
                            ______________________

                              Franklin Pass, M.D.
                              1840 Berkshire Lane
                         Minneapolis, Minnesota 55441
                         ----------------------------
                    (Name and address of agent for service)
                                (612) 553-1102
                                --------------
         (Telephone number, including area code, of agent for service)
                             ____________________

                                   Copy to:
                                 Amy E. Lange
                             Dorsey & Whitney LLP
                            220 South Sixth Street
                      Minneapolis, Minnesota  55402-1498
                             ____________________

     Approximate date of commencement of proposed sale to the public: from time
to time after the effective date of this Registration Statement.

                        CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>

                                             Proposed            Proposed
  Title of each class                    Maximum Offering        Maximum
  of Securities to be     Amount to be        Price         Aggregate Offering      Amount of
       registered          registered      per Unit (1)         Price (1)        Registration Fee
-------------------------------------------------------------------------------------------------
<S>                       <C>            <C>                <C>                  <C>
  Common Stock
  ($.01 par value)        995,050 (2)         $5.125            $5,099,631            $1,546
</TABLE>
(1)  Estimated solely for the purpose of calculating the registration fee, based
     upon the average of the high and low prices of the Common Stock as reported
     by the Nasdaq National Market on January 17, 1997.
(2)  495,050 shares of Common Stock are being registered under the Medi-Ject
     Corporation 1993 Stock Option Plan and 500,000 shares of Common Stock are
     being registered under the Medi-Ject Corporation 1996 Stock Option Plan.
<PAGE>
 
                                   PART II.
              INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.  Incorporation of Documents by Reference.
         --------------------------------------- 

          The following documents, which have been filed by Medi-Ject
Corporation (the "Company") with the Securities and Exchange Commission (the
"Commission"), are incorporated by reference in this Registration Statement, as
of their respective dates:

          (1)  The Prospectus, dated October 2, 1996, contained in the Company's
     Registration Statement on Form S-1 (File No. 333-6661);

          (2)  The Company's Quarterly Report on Form 10-Q for the quarter ended
     September 30, 1996; and

          (3)  The description of the Company's Common Stock contained in the
     Company's Registration Statement on Form 8-A, dated August 21, 1996, and
     any amendment or report filed to update such description filed subsequent
     to the date of this Prospectus and prior to the termination of the offering
     of the Common Stock offered hereby.

          All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Securities Exchange Act of 1934 subsequent to the date hereof
and prior to the filing of a post-effective amendment which indicates that all
securities offered hereby have been sold or which deregisters all securities
remaining unsold, shall be deemed to be incorporated by reference herein and to
be a part hereof from the respective dates of filing of such documents.

Item 6.  Indemnification of Directors and Officers.
         ----------------------------------------- 

          The Company's Bylaws and the statutes of the State of Minnesota
require the Company to indemnify any director, officer, employee or agent who
was or is a party to any threatened, pending or completed action, suit or
proceedings, whether civil, criminal, administrative or investigative, against
certain liabilities and expenses incurred in connection with the action, suit or
proceeding, except where such persons have not acted in good faith or did not
reasonably believe that the conduct was in the best interests of the Company.

          Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers or other persons
controlling the Company pursuant to the foregoing provisions, the Company has
been informed that in the opinion of the Commission, such indemnification is
against public policy as expressed in the Securities Act and is therefore
unenforceable.

Item 8.  Exhibits.
         -------- 

     4.1  Second Amended and restated Articles of Incorporation of the Company
          (incorporated by reference to the Company's Registration Statement on
          Form S-1, dated June 24, 1996 (File No. 333-6661) as amended on August
          15, 1996, September 27, 1996 and October 1, 1996)
     
     4.2  Second Amended and Restated Bylaws of the Company (incorporated by
          reference to the Company's Registration Statement on Form S-1, dated
          June 24, 1996 (File No. 333-6661) as amended on August 15, 1996,
          September 27, 1996 and October 1, 1996)

     5    Opinion of Dorsey & Whitney LLP

     23.1 Consent of KPMG Peat Marwick LLP, independent accountants

     23.2 Consent of Dorsey & Whitney LLP (included in Exhibit 5 above)

     24   Power of Attorney
<PAGE>
 
Item 9.  Undertakings.

A.  Post-Effective Amendments.

          The undersigned issuer hereby undertakes:

          (1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:

          (a)  To include any prospectus required by Section 10(a)(3) of the
               Securities Act;

          (b)  To reflect in the prospectus any facts or events arising after
               the effective date of the registration statement (or most recent
               post-effective amendment thereof) which, individually or in the
               aggregate, represent a fundamental change in the information set
               forth in the registration statement. Notwithstanding the
               foregoing, any increase or decrease in volume of securities
               offered (if the total dollar value of securities offered would
               not exceed that which was registered) and any deviation from the
               low or high end of the estimated maximum offering range may be
               reflected in the form of prospectus filed with the Commission
               pursuant to Rule 424(b) if, in the aggregate, the changes in
               volume and price represent no more than a 20% change in the
               maximum aggregate offering price set forth in the "Calculation of
               Registration Fee" table in the effective registration statement.

          (c)  To include any material information with respect to the plan of
               distribution not previously disclosed in the registration
               statement or any material change to such information in the
               registration statement;

provided, however, that subparagraphs (a) and (b) above will not apply if the
information required to be included in a post-effective amendment by those
subparagraphs is contained in periodic reports filed with or furnished to the
Commission by the registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in this
registration statement.

          (2)  That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.

          (3)  To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.

B.  Subsequent Documents Incorporated by Reference.

          The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

                                      -2-
<PAGE>
 
C.  Claims for Indemnification.

          Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable.  In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or other controlling person of the
registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.

                                      -3-
<PAGE>
 
                                  SIGNATURES

          Pursuant to the requirements of the Securities Act, the registrant
certifies that it has reasonable grounds to believe it meets all of the
requirements for filing on Form S-8 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Minneapolis, State of Minnesota, on this 24th day of
January, 1997.

                                       Medi-Ject Corporation

                                       By:/s/ Franklin Pass, M.D.
                                          ---------------------------------   
                                          Franklin Pass, M.D.
                                          President and Chief Executive Officer

          Pursuant to the requirements of the Securities Act, this registration
statement has been signed below by the following persons in the capacities and
on the date indicated:


Dated:  January 24, 1997



SIGNATURE                         TITLE
---------                         -----

/s/ Franklin Pass, M.D.    President, Chief Executive Officer and Director
-----------------------    (principal executive officer)
Franklin Pass, M.D.   

/s/ Mark Derus             Vice President of Finance, Chief Financial
-----------------------    Officer (principal financial and accounting
Mark Derus                 officer)

 
         *                 Director
-----------------------
Louis Cosentino

         *                 Director
-----------------------
Kenneth Evenstad

         *                 Director
-----------------------
Geoffrey Guy

         *                 Director
----------------------
Norman Jacobs

         *                 Director
----------------------
Fred Shapiro, M.D.

         *                 Director
----------------------
Peter Sjostrand

*By:/s/ Franklin Pass, M.D.
    ------------------------
        Franklin Pass, M.D.,
          Attorney-In-Fact

                                      -4-
<PAGE>
 
                                 EXHIBIT INDEX
                                 -------------


Exhibit
Number         Exhibit
------         -------

5              Opinion of Dorsey & Whitney LLP

23.1           Consent of KPMG Peat Marwick LLP, independent accountants

24             Power of Attorney
[{"type": "S-8", "sequence": "1", "description": "FORM S-8", "secsgml_size_bytes": 13967}]
{"company-data": {"conformed-name": "MEDI JECT CORP /MN/", "cik": "0001016169", "assigned-sic": "3841", "irs-number": "411350192", "state-of-incorporation": "MN", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-20389", "film-number": "97510611"}, "business-address": {"street1": "1840 BERKSHIRE LANE", "city": "MINNEAPOLIS", "state": "MN", "zip": "55441", "phone": "6125531102"}, "mail-address": {"street1": "1840 BERKSHIRE LANE", "city": "PLYMOUTH", "state": "MN", "zip": "55431"}}
As filed with the Securities and Exchange Commission on January 24, 1997.

                                                     Registration No.  333-_____
 
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C.  20549
                             ____________________
                                   FORM S-8
                            REGISTRATION STATEMENT
                                     Under
                              The Securities Act
                              __________________

                             MEDI-JECT CORPORATION
                             ---------------------
            (Exact name of registrant as specified in its charter)
Minnesota                                                                         41-1350192
                          ---------                                                                         ----------
(State or other jurisdiction of incorporation or organization)                                 (I.R.S. Employer Identification No.)
1840 Berkshire Lane
                         Minneapolis, Minnesota 55441
                         ----------------------------
              (Address of principal executive offices) (Zip code)

                            1993 STOCK OPTION PLAN
                                      AND
                            1996 STOCK OPTION PLAN
                             (Full title of plans)
                            ______________________

                              Franklin Pass, M.D.
                              1840 Berkshire Lane
                         Minneapolis, Minnesota 55441
                         ----------------------------
                    (Name and address of agent for service)
                                (612) 553-1102
                                --------------
         (Telephone number, including area code, of agent for service)
                             ____________________

                                   Copy to:
                                 Amy E. Lange
                             Dorsey & Whitney LLP
                            220 South Sixth Street
                      Minneapolis, Minnesota  55402-1498
                             ____________________

     Approximate date of commencement of proposed sale to the public: from time
to time after the effective date of this Registration Statement.

                        CALCULATION OF REGISTRATION FEE
Proposed            Proposed
  Title of each class                    Maximum Offering        Maximum
  of Securities to be     Amount to be        Price         Aggregate Offering      Amount of
       registered          registered      per Unit (1)         Price (1)        Registration Fee
-------------------------------------------------------------------------------------------------
Common Stock
  ($.01 par value)        995,050 (2)         $5.125            $5,099,631            $1,546
(1)  Estimated solely for the purpose of calculating the registration fee, based
     upon the average of the high and low prices of the Common Stock as reported
     by the Nasdaq National Market on January 17, 1997.
(2)  495,050 shares of Common Stock are being registered under the Medi-Ject
     Corporation 1993 Stock Option Plan and 500,000 shares of Common Stock are
     being registered under the Medi-Ject Corporation 1996 Stock Option Plan.
PART II.
              INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3.  Incorporation of Documents by Reference.
         --------------------------------------- 

          The following documents, which have been filed by Medi-Ject
Corporation (the "Company") with the Securities and Exchange Commission (the
"Commission"), are incorporated by reference in this Registration Statement, as
of their respective dates:

          (1)  The Prospectus, dated October 2, 1996, contained in the Company's
     Registration Statement on Form S-1 (File No. 333-6661);

          (2)  The Company's Quarterly Report on Form 10-Q for the quarter ended
     September 30, 1996; and

          (3)  The description of the Company's Common Stock contained in the
     Company's Registration Statement on Form 8-A, dated August 21, 1996, and
     any amendment or report filed to update such description filed subsequent
     to the date of this Prospectus and prior to the termination of the offering
     of the Common Stock offered hereby.

          All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Securities Exchange Act of 1934 subsequent to the date hereof
and prior to the filing of a post-effective amendment which indicates that all
securities offered hereby have been sold or which deregisters all securities
remaining unsold, shall be deemed to be incorporated by reference herein and to
be a part hereof from the respective dates of filing of such documents.

Item 6.  Indemnification of Directors and Officers.
         ----------------------------------------- 

          The Company's Bylaws and the statutes of the State of Minnesota
require the Company to indemnify any director, officer, employee or agent who
was or is a party to any threatened, pending or completed action, suit or
proceedings, whether civil, criminal, administrative or investigative, against
certain liabilities and expenses incurred in connection with the action, suit or
proceeding, except where such persons have not acted in good faith or did not
reasonably believe that the conduct was in the best interests of the Company.

          Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers or other persons
controlling the Company pursuant to the foregoing provisions, the Company has
been informed that in the opinion of the Commission, such indemnification is
against public policy as expressed in the Securities Act and is therefore
unenforceable.

Item 8.  Exhibits.
         -------- 

     4.1  Second Amended and restated Articles of Incorporation of the Company
          (incorporated by reference to the Company's Registration Statement on
          Form S-1, dated June 24, 1996 (File No. 333-6661) as amended on August
          15, 1996, September 27, 1996 and October 1, 1996)
     
     4.2  Second Amended and Restated Bylaws of the Company (incorporated by
          reference to the Company's Registration Statement on Form S-1, dated
          June 24, 1996 (File No. 333-6661) as amended on August 15, 1996,
          September 27, 1996 and October 1, 1996)

     5    Opinion of Dorsey & Whitney LLP

     23.1 Consent of KPMG Peat Marwick LLP, independent accountants

     23.2 Consent of Dorsey & Whitney LLP (included in Exhibit 5 above)

     24   Power of Attorney
Item 9.  Undertakings.

A.  Post-Effective Amendments.

          The undersigned issuer hereby undertakes:

          (1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:

          (a)  To include any prospectus required by Section 10(a)(3) of the
               Securities Act;

          (b)  To reflect in the prospectus any facts or events arising after
               the effective date of the registration statement (or most recent
               post-effective amendment thereof) which, individually or in the
               aggregate, represent a fundamental change in the information set
               forth in the registration statement. Notwithstanding the
               foregoing, any increase or decrease in volume of securities
               offered (if the total dollar value of securities offered would
               not exceed that which was registered) and any deviation from the
               low or high end of the estimated maximum offering range may be
               reflected in the form of prospectus filed with the Commission
               pursuant to Rule 424(b) if, in the aggregate, the changes in
               volume and price represent no more than a 20% change in the
               maximum aggregate offering price set forth in the "Calculation of
               Registration Fee" table in the effective registration statement.

          (c)  To include any material information with respect to the plan of
               distribution not previously disclosed in the registration
               statement or any material change to such information in the
               registration statement;

provided, however, that subparagraphs (a) and (b) above will not apply if the
information required to be included in a post-effective amendment by those
subparagraphs is contained in periodic reports filed with or furnished to the
Commission by the registrant pursuant to Section 13 or Section 15(d) of the
Securities Exchange Act of 1934 that are incorporated by reference in this
registration statement.

          (2)  That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.

          (3)  To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the
termination of the offering.

B.  Subsequent Documents Incorporated by Reference.

          The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Securities Exchange Act of 1934 that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.

                                      -2-
C.  Claims for Indemnification.

          Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act
and is, therefore, unenforceable.  In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or other controlling person of the
registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is
against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.

                                      -3-
SIGNATURES

          Pursuant to the requirements of the Securities Act, the registrant
certifies that it has reasonable grounds to believe it meets all of the
requirements for filing on Form S-8 and has duly caused this registration
statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Minneapolis, State of Minnesota, on this 24th day of
January, 1997.

                                       Medi-Ject Corporation

                                       By:/s/ Franklin Pass, M.D.
                                          ---------------------------------   
                                          Franklin Pass, M.D.
                                          President and Chief Executive Officer

          Pursuant to the requirements of the Securities Act, this registration
statement has been signed below by the following persons in the capacities and
on the date indicated:

Dated:  January 24, 1997

SIGNATURE                         TITLE
---------                         -----

/s/ Franklin Pass, M.D.    President, Chief Executive Officer and Director
-----------------------    (principal executive officer)
Franklin Pass, M.D.   

/s/ Mark Derus             Vice President of Finance, Chief Financial
-----------------------    Officer (principal financial and accounting
Mark Derus                 officer)

 
         *                 Director
-----------------------
Louis Cosentino

         *                 Director
-----------------------
Kenneth Evenstad

         *                 Director
-----------------------
Geoffrey Guy

         *                 Director
----------------------
Norman Jacobs

         *                 Director
----------------------
Fred Shapiro, M.D.

         *                 Director
----------------------
Peter Sjostrand

*By:/s/ Franklin Pass, M.D.
    ------------------------
        Franklin Pass, M.D.,
          Attorney-In-Fact

                                      -4-
EXHIBIT INDEX
                                 -------------

Exhibit
Number         Exhibit
------         -------

5              Opinion of Dorsey & Whitney LLP

23.1           Consent of KPMG Peat Marwick LLP, independent accountants

24             Power of Attorney